Sarah Cannon Research Institute in Nashville, Tennessee and MD Anderson Cancer Center in Houston, Texas are the first enrolling sites in this multi-center, global trial.
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and anti-tumor activity of SL-279252 in patients with advanced solid tumors or lymphomas.
Takeda Pharmaceutical Company currently holds an exclusive option to enter into a license to develop and commercialize SL-279252.
SL-279252 is a novel therapeutic derived from Shattuck's proprietary Agonist Redirected Checkpoint platform and its first molecule to begin clinical trials.
The dual-sided nature of SL-279252 is designed to simultaneously block the PD-L1 inhibitory signal and stimulate OX40 signaling.
Preclinical studies have demonstrated that SL-279252 potently stimulates anti-tumor T cell activity.
Shattuck is a clinical-stage biopharmaceutical company developing its Agonist Redirected Checkpoint platform, a novel class of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases.
Using its proprietary ARC platform, Shattuck is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. Shattuck has offices in Austin, Texas and Durham, North Carolina.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007